STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYRX
  4. [Form 4] CryoPort, Inc. Insider Trading Activity

CryoPort Insider Exercises 20K Options, Sells 13K Shares at $7

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CryoPort (NASDAQ:CYRX) filed a Form 4 reporting insider activity by director Ramkumar Mandalam on 24 Jun 2025.

The director exercised 20,000 options at $3.07, then sold 13,321 shares at a weighted-average price of $7.015. Net effect is a 6,679-share increase, lifting direct ownership 10% to 73,056 shares. Remaining derivative holdings total 60,000 options.

The open-market sale represents about 18% of his post-transaction stake and generated roughly $93k in proceeds. All trades were executed under a Rule 10b5-1 plan adopted 10 Jun 2025.

No other executives were involved and no strategic disclosures accompanied the filing.

Positive

  • Net increase of 6,679 shares (+10% vs pre-transaction) indicates the director retains meaningful ownership after exercising options.

Negative

  • Open-market sale of 13,321 shares (~18% of holdings) for ~$93k may be viewed as partial profit-taking.

Insights

TL;DR: Mixed signal—director sells 18% but still ups stake 10%.

The transaction is modest in dollar terms (~$93k) yet material by ownership percentage. Exercising at $3.07 and selling part at $7.015 locks in a healthy spread while leaving the insider with a larger absolute position. The pre-planned 10b5-1 reduces informational value, so share-price impact should be muted. Overall, sentiment appears neutral: profit-taking offset by continued exposure.

TL;DR: Limited portfolio relevance; no change to CYRX thesis.

The sale equals just 0.2 days’ average volume and won’t pressure liquidity. Net share addition suggests no imminent bearish view. Absence of accompanying business news or guidance keeps the event immaterial to cash-flow forecasts. Investors may note the options’ August 2025 expiry, but unless further selling emerges, this filing does not alter risk-reward dynamics.

Insider Mandalam Ramkumar
Role Director
Sold 13,321 shs ($93K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 20,000 $0.00 --
Exercise Common Stock 20,000 $3.07 $61K
Sale Common Stock 13,321 $7.015 $93K
Holdings After Transaction: Stock Option (right to buy) — 60,000 shares (Direct); Common Stock — 86,377 shares (Direct)
Footnotes (1)
  1. This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on June 10, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.07, inclusive. 1/48 of the options vested on the 19th of each month for forty-eight months beginning on 8/19/2015.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mandalam Ramkumar
(Last) (First) (Middle)
C/O CRYOPORT INC.
112 WESTWOOD PLACE, SUITE 350
(Street)
BRENTWOOD TN 37027
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/24/2025 M 20,000(1) A $3.07 86,377 D
Common Stock 06/24/2025 S 13,321(1) D $7.015(2) 73,056 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $3.07 06/24/2025 M 20,000(1) (3) 08/20/2025 Common Stock 20,000 $0.00 60,000 D
Explanation of Responses:
1. This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on June 10, 2025.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.07, inclusive.
3. 1/48 of the options vested on the 19th of each month for forty-eight months beginning on 8/19/2015.
Remarks:
With respect to prices reported as weighted average prices in Table I, the reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the applicable footnotes to this Form 4.
/s/ Ramkumar Mandalam 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many CryoPort shares did director Ramkumar Mandalam sell on 24 Jun 2025?

He sold 13,321 shares of CYRX common stock at an average price of $7.015.

At what price were the CYRX options exercised in June 2025?

The director exercised 20,000 options at $3.07 per share.

What is Ramkumar Mandalam's current CYRX shareholding after the transaction?

He now holds 73,056 shares directly and retains 60,000 unexercised options.

Was the June 2025 CYRX transaction executed under a 10b5-1 plan?

Yes. The Form 4 states it was carried out under a trading plan adopted on 10 Jun 2025.

How much cash did the director realize from the CYRX share sale?

Approximate proceeds were $93,500 (13,321 × $7.015 weighted-average price).